Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $3,185,700.00 in Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 105,000 shares of the company’s stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $30.34, for a total value of $3,185,700.00. Following the completion of the transaction, the chief accounting officer directly owned 24,353 shares in the company, valued at $738,870.02. The trade was a 81.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Louise Frederika Kooij also recently made the following trade(s):

• On Monday, June 22nd, Louise Frederika Kooij sold 40,000 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $30.20, for a total value of $1,208,000.00.
• On Tuesday, May 26th, Louise Frederika Kooij sold 65,000 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.69, for a total value of $2,319,850.00.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ NAMS opened at $28.46 on Friday. The stock’s fifty day moving average price is $32.31 and its two-hundred day moving average price is $32.69. NewAmsterdam Pharma Company N.V. has a one year low of $21.14 and a one year high of $42.21. The firm has a market cap of $3.33 billion, a price-to-earnings ratio of -15.90 and a beta of 0.08.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The firm had revenue of $3.04 million for the quarter. On average, equities analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.78 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have weighed in on NAMS shares. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. BMO Capital Markets assumed coverage on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. They set an “outperform” rating and a $58.00 target price on the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a $45.00 target price on shares of NewAmsterdam Pharma in a report on Monday, July 20th. Royal Bank Of Canada lifted their price target on shares of NewAmsterdam Pharma from $47.00 to $51.00 and gave the company an “outperform” rating in a research report on Tuesday, June 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, NewAmsterdam Pharma presently has an average rating of “Moderate Buy” and a consensus target price of $49.42.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several hedge funds and other institutional investors have recently modified their holdings of NAMS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of NewAmsterdam Pharma during the 1st quarter worth $610,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in NewAmsterdam Pharma by 13.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 288,134 shares of the company’s stock valued at $5,898,000 after acquiring an additional 34,563 shares during the last quarter. Geode Capital Management LLC raised its stake in NewAmsterdam Pharma by 15.9% during the second quarter. Geode Capital Management LLC now owns 99,457 shares of the company’s stock worth $1,800,000 after acquiring an additional 13,629 shares in the last quarter. Legal & General Group Plc raised its stake in NewAmsterdam Pharma by 33.5% during the second quarter. Legal & General Group Plc now owns 44,235 shares of the company’s stock worth $801,000 after acquiring an additional 11,106 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of NewAmsterdam Pharma by 12.7% in the second quarter. Invesco Ltd. now owns 134,035 shares of the company’s stock worth $2,427,000 after acquiring an additional 15,101 shares during the last quarter. Institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical?stage biopharmaceutical company focused on discovering and developing novel small?molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small?molecule candidates at various stages of preclinical and clinical evaluation.